p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas.

@article{Redman2001p38KI,
  title={p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas.},
  author={Anik{\'o} M Redman and Jeffrey S Johnson and Robert D Dally and Stephen G Swartz and Hanno Wild and Holger Paulsen and Yolanda Caringal and David Gunn and Joel Renick and Martin H. Osterhout and Jill E. Kingery-Wood and Roger Abbey Smith and Wendy S. C. Lee and Jacques Dumas and Scott M. Wilhelm and Timothy J Housley and Ajay Bhargava and Gerald E Ranges and Alka Shrikhande and Donna L W Young and Marek Bombara and William J. Scott},
  journal={Bioorganic & medicinal chemistry letters},
  year={2001},
  volume={11 1},
  pages={9-12}
}
Inhibitors of the MAP kinase p38 are potentially useful for the treatment for osteoporosis, arthritis, and other inflammatory diseases. A series of thienyl, furyl, and pyrrolyl ureas has been identified as potent p38 inhibitors, displaying in vitro activity in the nanomolar range. 

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…